CNS Spectrums最新文献_第8页

What is the neurobiology of schizophrenia? 精神分裂症的神经生物学原理是什么？

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-10-30 DOI: 10.1017/S1092852924000518

Michael A Cummings, Ai-Li W Arias, Stephen M Stahl

{"title":"What is the neurobiology of schizophrenia?","authors":"Michael A Cummings, Ai-Li W Arias, Stephen M Stahl","doi":"10.1017/S1092852924000518","DOIUrl":"10.1017/S1092852924000518","url":null,"abstract":"Schizophrenia spectrum disorders are brain diseases that are developmental dementias (dementia praecox). Their pathology begins in utero with psychosis most commonly becoming evident in adolescence and early adulthood. It is estimated they afflict the U.S. population at a prevalence rate of approximately 0.8%. Genetic studies indicate that these brain diseases are about 80% determined by genes and about 20% determined by environmental risk factors. Inheritance is polygenic with some 270 gene loci having been identified as contributing to the risk for schizophrenia. Interestingly, many of the identified gene loci and gene polymorphisms are involved in brain formation and maturation. The identified genetic and epigenetic risks give rise to a brain in which neuroblasts migrate abnormally, assume abnormal locations and orientations, and are vulnerable to excessive neuronal and synaptic loss, resulting in overt psychotic illness. The illness trajectory of schizophrenia then is one of loss of brain mass related to the number of active psychotic exacerbations and the duration of untreated illness. In this context, molecules such as dopamine, glutamate, and serotonin play critical roles with respect to positive, negative, and cognitive domains of illness. Acutely, antipsychotics ameliorate active psychotic illness, especially positive signs and symptoms. The long-term effects of antipsychotic medications have been debated; however, the bulk of imaging data suggest that antipsychotics slow but do not reverse the illness trajectory of schizophrenia. Long-acting injectable antipsychotics (LAI) appear superior in this regard. Clozapine remains the \"gold standard\" in managing treatment-resistant schizophrenia.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"e13"},"PeriodicalIF":3.4,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical management model for impulse control disorders in Parkinson's disease. 帕金森病冲动控制障碍的临床管理模式。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-10-29 DOI: 10.1017/S1092852924000403

Han Li, Yong Yang, Liying Yang, Anmu Xie

{"title":"Clinical management model for impulse control disorders in Parkinson's disease.","authors":"Han Li, Yong Yang, Liying Yang, Anmu Xie","doi":"10.1017/S1092852924000403","DOIUrl":"https://doi.org/10.1017/S1092852924000403","url":null,"abstract":"Over the last decade, we have gained a better understanding of impulse control disorder in Parkinson's disease (PD-ICD), a medication complication in PD. Researchers were aware of its complexity and took efforts to learn more about its diagnostic and treatment possibilities. Nevertheless, clinical management for it is currently neglected. We conducted a narrative overview of literature published from 2012 to October 2023 on various aspects of clinical management for PD-ICD. A potential \"susceptibility-catalytic-stress\" model in the development of PD-ICD was proposed and a profile encoding predictors for PD-ICD was created. Based on these predictors, some methods for prediction were recently developed for better prediction, such as the polymorphic dopamine genetic risk score and the clinic-genetic ICD-risk score. A variety of treatment options, including dose reduction of dopamine receptor agonists (DAs), DAs removal, DAs switch, and add-on therapy, are investigated with inconsistent reports. Based on current findings, we developed a clinical management model prototype centered on prevention, consisting of prediction, prevention, follow-up and monitoring, therapy, and recurrence prevention, for clinical reference, and further proposed 4 key clinical management principles, including standardization, prediction centered, persistence, and whole course.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can total electrical energy (TEED) after subthalamic DBS alter verbal fluency in Parkinson's disease patients? A preliminary evidence. 帕金森病患者脑下垂体电刺激术后的总电能（TEED）会改变其言语流畅性吗？初步证据。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-10-28 DOI: 10.1017/S1092852924000439

Fabiana Ruggiero, Francesca Mameli, Edoardo Nicolò Aiello, Eleonora Zirone, Filippo Cogiamanian, Linda Borellini, Elena Pirola, Antonella Ampollini, Barbara Poletti, Angelica De Sandi, Marco Prenassi, Sara Marceglia, Nicola Ticozzi, Vincenzo Silani, Marco Locatelli, Giordano D'Urso, Sergio Barbieri, Alberto Priori, Roberta Ferrucci

{"title":"Can total electrical energy (TEED) after subthalamic DBS alter verbal fluency in Parkinson's disease patients? A preliminary evidence.","authors":"Fabiana Ruggiero, Francesca Mameli, Edoardo Nicolò Aiello, Eleonora Zirone, Filippo Cogiamanian, Linda Borellini, Elena Pirola, Antonella Ampollini, Barbara Poletti, Angelica De Sandi, Marco Prenassi, Sara Marceglia, Nicola Ticozzi, Vincenzo Silani, Marco Locatelli, Giordano D'Urso, Sergio Barbieri, Alberto Priori, Roberta Ferrucci","doi":"10.1017/S1092852924000439","DOIUrl":"https://doi.org/10.1017/S1092852924000439","url":null,"abstract":"Objective: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves motor outcomes in Parkinson's disease (PD) but may have adverse long-term effects on specific cognitive domains. The aim of this study was to investigate the association between total electrical energy (TEED) delivered by DBS and postoperative changes in verbal fluency.Methods: Seventeen PD patients undergoing bilateral STN-DBS were assessed with the Alternate Verbal Fluency Battery (AVFB), which includes phonemic (PVF), semantic (SVF), and alternate verbal fluency (AVF) tests, before surgery (T0) and after 6 (T1) and 12 months (T2). Bilateral TEED and average TEEDM were recorded at T1 and T2. For each AVFB measurement, changes from T0 to T1 (Δ-01) and from T0 to T2 (Δ-02) were calculated.Results: At T1, PVF (p = 0.007) and SVF scores (p = 0.003) decreased significantly. TEED measures at T1 and T2 were unrelated to Δ-01 and Δ-02 scores, respectively. However, an inverse, marginally significant association was detected between the TEEDM and Δ-01 scores for the AVF (p = 0.041, against an αadjusted = 0.025).Conclusions: In conclusion, the present reports provide preliminary evidence that TEED may not be responsible or only slightly responsible for the decline in VF performance after STN-DBS in PD.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"1-4"},"PeriodicalIF":3.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence-based treatment for schizophrenia: a personal perspective. 精神分裂症的循证治疗：个人观点。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-10-28 DOI: 10.1017/S1092852924000555

Bethany Yeiser

引用次数: 0

Failure to treat: an American policy perspective. 治疗失败：美国的政策视角。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-10-28 DOI: 10.1017/S1092852924000543

Katherine Warburton

{"title":"Failure to treat: an American policy perspective.","authors":"Katherine Warburton","doi":"10.1017/S1092852924000543","DOIUrl":"10.1017/S1092852924000543","url":null,"abstract":"Throughout its two and a half centuries in existence, US mental health policy has repeatedly failed people living with schizophrenia. The failures are cyclical-the inhumane conditions uncovered in the first 75 years of existence were addressed with the construction of state asylums to deliver moral treatment. One hundred years later, the asylums were themselves revealed to be inhumane. Deinstitutionalization, the response to the failure of asylums starting in the 1960s, now drives outcomes such as homelessness, incarceration, and early death for people living with psychotic illnesses. In all cases, well-intentioned policy reform has failed at the level of implementation, largely due to a lack of accountability. The result has been a consistent failure to adequately treat people living with schizophrenia, which is now understood to be a highly treatable condition. As the country passes into a quarter millennium in existence, reform is once again underway. Unlike other points in history, there is good news. Other countries, such as Italy, have successfully leveraged reform to achieve greatly improved outcomes. Understanding US history and the successful implementation of policy change in other countries is imperative and teaches us that accountability in implementation is necessary to break the cycle of policy failure.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"e14"},"PeriodicalIF":3.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of vortioxetine versus desvenlafaxine in the treatment of functional impairment in patients with major depressive disorder: Results from the multinational VIVRE study. 伏替西汀与去文拉法辛治疗重度抑郁症患者功能障碍的疗效：多国 VIVRE 研究结果。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-10-28 DOI: 10.1017/S1092852924000610

Michael Cronquist Christensen, Iria Grande, Andreas Rieckmann, Pratap Chokka

{"title":"Efficacy of vortioxetine versus desvenlafaxine in the treatment of functional impairment in patients with major depressive disorder: Results from the multinational VIVRE study.","authors":"Michael Cronquist Christensen, Iria Grande, Andreas Rieckmann, Pratap Chokka","doi":"10.1017/S1092852924000610","DOIUrl":"https://doi.org/10.1017/S1092852924000610","url":null,"abstract":"Background: In VIVRE (NCT04448431), vortioxetine was associated with significantly higher rates of symptomatic and functional remission, better daily and social functioning, and greater treatment satisfaction than desvenlafaxine in patients with major depressive disorder (MDD) and partial response to selective serotonin reuptake inhibitor (SSRI) therapy. This analysis further explored the relative improvement in patient functioning with vortioxetine versus desvenlafaxine.Methods: VIVRE was a randomized, double-blind study of vortioxetine (10 or 20 mg/day) versus desvenlafaxine (50 mg/day) in adults with MDD and partial response to initial SSRI monotherapy. Mean percentage changes from baseline to week 8 in Functioning Assessment Short Test (FAST) total and domain scores were analyzed by treatment group in the overall population and in working patients.Results: In the overall population, the mean reduction in FAST total score from baseline after 8 weeks of treatment was 37.2% in vortioxetine-treated patients versus 31.8% in desvenlafaxine-treated patients (P = 0.04). Significantly greater improvements versus desvenlafaxine were seen in vortioxetine-treated patients for FAST autonomy, cognitive functioning, and interpersonal-relationships scores (all P < 0.05). In working patients, the mean reduction in FAST total score from baseline at week 8 was 38.7% versus 32.1% in the vortioxetine and desvenlafaxine groups, respectively (P = 0.04). Significant correlations were seen between absolute changes in patient functioning, and those in depression severity and health-related quality of life.Conclusion: Vortioxetine was significantly better than desvenlafaxine in improving overall functioning as well as daily, social, and cognitive functioning in patients with MDD with inadequate response to prior SSRI therapy.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the pathophysiology of agitation in Alzheimer's dementia with a focus on neurotransmitters and circuits. 概述阿尔茨海默氏症痴呆症患者躁动的病理生理学，重点关注神经递质和神经回路。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-10-23 DOI: 10.1017/S1092852924000427

Jeffrey L Cummings, Malaak Brubaker, Katherine J Selzler, Sarah T Gonzalez, Mehul Patel, Stephen M Stahl

{"title":"An overview of the pathophysiology of agitation in Alzheimer's dementia with a focus on neurotransmitters and circuits.","authors":"Jeffrey L Cummings, Malaak Brubaker, Katherine J Selzler, Sarah T Gonzalez, Mehul Patel, Stephen M Stahl","doi":"10.1017/S1092852924000427","DOIUrl":"https://doi.org/10.1017/S1092852924000427","url":null,"abstract":"Alzheimer's dementia (AD) is a progressive, neurodegenerative disease often accompanied by neuropsychiatric symptoms that profoundly impact both patients and caregivers. Agitation is among the most prevalent and distressing of these symptoms and often requires treatment. Appropriate therapeutic interventions depend on understanding the biological basis of agitation and how it may be affected by treatment. This narrative review discusses a proposed pathophysiology of agitation in Alzheimer's dementia based on convergent evidence across research approaches. Available data indicate that agitation in Alzheimer's dementia is associated with an imbalance of activity between key prefrontal and subcortical brain regions. The monoamine neurotransmitter systems serve as key modulators of activity within these brain regions and circuits and are rendered abnormal in AD. Patients with AD who exhibited agitation symptoms during life have alterations in neurotransmitter nuclei and related systems when the brain is examined at autopsy. The authors present a model of agitation in Alzheimer's dementia in which noradrenergic hyperactivity along with serotonergic deficits and dysregulated striatal dopamine release contribute to agitated and aggressive behaviors.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Association Between Dextromethorphan/Bupropion with Alcohol and Substance Misuse: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). 右美沙芬/安非他酮与酗酒和药物滥用的关系：向食品药品管理局不良事件报告系统（FAERS）提交的报告。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-10-23 DOI: 10.1017/S1092852924000415

Angela T H Kwan, Roger S McIntyre

{"title":"The Association Between Dextromethorphan/Bupropion with Alcohol and Substance Misuse: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).","authors":"Angela T H Kwan, Roger S McIntyre","doi":"10.1017/S1092852924000415","DOIUrl":"https://doi.org/10.1017/S1092852924000415","url":null,"abstract":"Objective: Dextromethorphan/bupropion (DXM/BUP) received Food and Drug Administration (FDA) approval for the treatment of adults with major depressive disorder (MDD) in August 2022. This combination is not known to have abuse liability and is not currently scheduled by the Drug Enforcement Administration (DEA). Notwithstanding, dextromethorphan is a drug of abuse. Herein, we sought to determine whether DXM/BUP has alcohol and/or substance misuse liability.Methods: We evaluated spontaneous reports of terms such as \"alcohol problem, alcoholism, alcohol abuse, substance dependence, substance use disorder (SUD), substance abuse, drug dependence, drug use disorder and drug abuse\" in the FDA Adverse Event Reporting System (FAERS). The FAERS is a spontaneous reporting database of adverse events submitted to the FDA.Results: We performed a comparative assessment of the alcohol and/or substance misuse liability of DXM/BUP since its market authorization in August 2022, using acetaminophen as the control. Dextromethorphan served as the upper-bound reference point. Our findings showed that, since August 2022, dextromethorphan had a significant reporting odds ratio (ROR) for \"drug abuse.\" In contrast, DXM/BUP did not have a significant ROR for any of the categories of alcohol and/or substance misuse evaluated. Limitations of our findings derive largely from the limitations of the FAERS and its data capture method.Conclusion: The absence of alcohol or substance misuse reported to the FAERS with DXM/BUP accords with the lack of evidence of abuse liability prior to FDA approval and its non-scheduling by the DEA.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"1-5"},"PeriodicalIF":3.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-suicidal self-injury in trichotillomania and skin picking disorder. 毛手毛脚症和抠皮症中的非自杀性自伤。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-08-01 Epub Date: 2024-05-17 DOI: 10.1017/S1092852924000294

Jon E Grant, Madison Collins

{"title":"Non-suicidal self-injury in trichotillomania and skin picking disorder.","authors":"Jon E Grant, Madison Collins","doi":"10.1017/S1092852924000294","DOIUrl":"10.1017/S1092852924000294","url":null,"abstract":"Background: Trichotillomania and skin picking disorder have been characterized as body-focused repetitive behavior (BFRB) disorders (i.e., repetitive self-grooming behaviors that involve biting, pulling, picking, or scraping one's own hair, skin, lips, cheeks, or nails). Trichotillomania and skin picking disorder have also historically been classified, by some, as types of compulsive self-injury as they involve repetitive hair pulling and skin picking, respectively. The question of the relationship of these disorders to more conventional forms of self-injury such as cutting or self-burning remains incompletely investigated. The objective of this study was to examine the relationship of these two disorders with non-suicidal self-injury (NSSI).Methods: Adults with trichotillomania (n = 93) and skin picking (n = 105) or both (n = 82) were recruited from the general population using advertisements and online support groups and completed an online survey. Participants completed self-report instruments to characterize clinical profiles and associated characteristics. In addition, each participant completed a mental health history questionnaire.Results: Of the 280 adults with BFRB disorders, 141 (50.1%) reported a history of self-injury independent of hair pulling and skin picking. Participants with a history of self-injury reported significantly worse pulling and picking symptoms (p < .001) and were significantly more likely to have co-occurring alcohol problems (p < .001), borderline personality disorder (p < .001), buying disorder (p < .001), gambling disorder (p < .001), compulsive sex behavior (p < 001), and binge eating disorder (p = .041).Conclusions: NSSI appears common in trichotillomania and skin picking disorder and may be part of a larger constellation of behaviors associated with impulse control or reward-related dysfunction.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"268-272"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world case series of maintenance theta burst stimulation therapy following response to acute theta burst stimulation therapy for difficult-to-treat depression. 对难以治疗的抑郁症进行急性西塔脉冲刺激疗法治疗后的维持性西塔脉冲刺激疗法真实世界案例系列。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2024-08-01 Epub Date: 2024-05-21 DOI: 10.1017/S109285292400035X

Yoshihiro Noda, Kyoshiro Fujii, Shinichiro Nakajima, Ryosuke Kitahata

{"title":"Real-world case series of maintenance theta burst stimulation therapy following response to acute theta burst stimulation therapy for difficult-to-treat depression.","authors":"Yoshihiro Noda, Kyoshiro Fujii, Shinichiro Nakajima, Ryosuke Kitahata","doi":"10.1017/S109285292400035X","DOIUrl":"10.1017/S109285292400035X","url":null,"abstract":"Objective: Treatment and management for difficult-to-treat depression are challenging, especially in a subset of patients who are at high risk for relapse and recurrence. The conditions that represent this subset are recurrent depressive disorder (RDD) and bipolar disorder (BD). In this context, we aimed to examine the effectiveness of maintenance transcranial magnetic stimulation (TMS) on a real-world clinical basis by retrospectively extracting data from the TMS registry data in Tokyo, Japan.Methods: Data on patients diagnosed with treatment-resistant RDD and BD who received maintenance intermittent theta burst stimulation (iTBS) weekly after successful treatment with acute iTBS between March 2020 and October 2023 were extracted from the registry.Results: All patients (21 cases: 10 cases with RDD and 11 cases with BD) could sustain response, and 19 of them further maintained remission. In this study, maintenance iTBS did not exacerbate depressive symptoms in any of the cases, but may rather have the effect of stabilizing the mental condition and preventing recurrence.Conclusions: This case series is of great clinical significance because it is the first study to report on the effectiveness of maintenance iTBS for RDD and BD, with a follow-up of more than 2 years. Further validation with a randomized controlled trial design with a larger sample size is warranted.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"279-288"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0